share_log

和黃醫藥:和黃醫藥收到美國FDA有關索凡替尼(Surufatinib)用於治療晚期神經內分泌瘤的完整回覆函

HUTCHMED: HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

May 2, 2022 06:09
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more